Literature DB >> 31849003

Multidisciplinary management of calciphylaxis: a series of 5 patients at a single facility.

Tomohiro Saito1, Yuuki Mima2, Motonori Sugiyama2, Nozomi Miyazawa2, Ayana Iida2, Nobuhiro Kanazawa2, Taihei Suzuki2, Yasuto Shikida2, Toma Hamada2, Yukihiro Wada2, Masahide Mizobuchi2, Hirokazu Honda2.   

Abstract

Calciphylaxis is a rare and severe disease that manifests with painful skin ulceration and necrosis. Herein, we report five patients of hemodialysis patients with skin biopsy-proven calciphylaxis at a single facility. One patient had undergone parathyroidectomy (PTx) due to severe secondary hyperparathyroidism, four had been treated with vitamin D receptor activators, and two were on warfarin therapy. All patients had hyperphosphatemia, and one had hypercalcemia. The intact parathyroid hormone level at diagnosis was 2 pg/ml in the patient after PTx, while three patients were within the target range. The average period after diagnosis of calciphylaxis was 2 months. Skin lesions were present on the thighs and lower legs in two patients, and on the dorsum of the foot in one patient. In skin biopsy, calcification was found in the arteriolar media in four patients, and calcium (Ca) was deposited in the dermal lesion in one patient. All patients received local cures, surgical debridement, antibiotics to control infectious diseases, and strict control of serum Ca and phosphate. Calcimimetics were used in all patients except one who had undergone PTx one month before, sodium thiosulfate was used in 4 patients, and low Ca dialysate was used in three patients. The average follow-up period was 7.4 months. Four patients were cured, and one died due to infection. We suggest that multidisciplinary management for infectious diseases, surgical debridement, strict control of mineral and bone markers from the early stage, and elimination of risk factors may improve the course of calciphylaxis, which is a life-threatening disease.

Entities:  

Keywords:  Calcific uremic arteriolopathy; Calcimimetics; Calciphylaxis; Hyperphosphatemia; Surgical debridement

Mesh:

Substances:

Year:  2019        PMID: 31849003      PMCID: PMC7148403          DOI: 10.1007/s13730-019-00439-8

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  31 in total

1.  A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

Authors:  Sagar U Nigwekar; Sophia Zhao; Julia Wenger; Jeffrey L Hymes; Franklin W Maddux; Ravi I Thadhani; Kevin E Chan
Journal:  J Am Soc Nephrol       Date:  2016-04-14       Impact factor: 10.121

2.  Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients.

Authors:  Emanuel Zitt; Matthias König; Andreas Vychytil; Martin Auinger; Manfred Wallner; Gernot Lingenhel; Gernot Schilcher; Michael Rudnicki; Hermann Salmhofer; Karl Lhotta
Journal:  Nephrol Dial Transplant       Date:  2013-01-04       Impact factor: 5.992

Review 3.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

Review 4.  Calciphylaxis: Controversies in Pathogenesis, Diagnosis and Treatment.

Authors:  Haneol S Jeong; Arturo R Dominguez
Journal:  Am J Med Sci       Date:  2016-02       Impact factor: 2.378

Review 5.  Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients.

Authors:  Ting Peng; Ling Zhuo; Ying Wang; Min Jun; Guisen Li; Li Wang; Daqing Hong
Journal:  Nephrology (Carlton)       Date:  2018-07       Impact factor: 2.506

6.  The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Authors:  Jürgen Floege; Yumi Kubo; Anna Floege; Glenn M Chertow; Patrick S Parfrey
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-17       Impact factor: 8.237

7.  Early clinical presentations and progression of calciphylaxis.

Authors:  Toshi Ghosh; Daniel S Winchester; Mark D P Davis; Rokea El-Azhary; Nneka I Comfere
Journal:  Int J Dermatol       Date:  2017-04-23       Impact factor: 2.736

8.  Sodium thiosulfate therapy for calcific uremic arteriolopathy.

Authors:  Sagar U Nigwekar; Steven M Brunelli; Debra Meade; Weiling Wang; Jeffrey Hymes; Eduardo Lacson
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 8.237

Review 9.  Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches.

Authors:  Kurt M Sowers; Melvin R Hayden
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

10.  Calciphylaxis in peritoneal dialysis patients: a single center cohort study.

Authors:  Yanchen Zhang; Kristin M Corapi; Maria Luongo; Ravi Thadhani; Sagar U Nigwekar
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.